Friday, 10 September 2010

Russian regulatory approval for Gilenya(R) oral multiple sclerosis therapy

From the MSRC:

Novartis International AG announced Russian regulatory approval for Gilenya(R), a once-daily oral multiple sclerosis therapy and first in a new class processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.   For more click here